Oxford Nanopore Technologies (LON:ONT) Shares Down 10.2% – What’s Next?

Oxford Nanopore Technologies plc (LON:ONT) traded down 10.2% on Monday . The company traded as low as GBX 127 ($1.59) and last traded at GBX 128.50 ($1.61). 3,354,197 shares changed hands during trading, an increase of 54% from the average session volume of 2,182,529 shares. The stock had previously closed at GBX 143.10 ($1.79).

Analysts Set New Price Targets

ONT has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 190 ($2.38) price target on shares of Oxford Nanopore Technologies in a research report on Wednesday, September 4th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Oxford Nanopore Technologies in a research report on Friday, December 6th. Finally, Berenberg Bank reiterated a “buy” rating and issued a GBX 282 ($3.54) target price on shares of Oxford Nanopore Technologies in a report on Tuesday, September 3rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of GBX 235.50 ($2.95).

Oxford Nanopore Technologies Stock Performance

The stock has a market cap of £1.21 billion, a PE ratio of -642.50 and a beta of 0.80. The company has a debt-to-equity ratio of 8.07, a quick ratio of 6.01 and a current ratio of 4.45. The company’s 50 day simple moving average is GBX 142.50 and its 200 day simple moving average is GBX 129.78.

Insiders Place Their Bets

In other Oxford Nanopore Technologies news, insider Gurdial (Gordon) Sanghera sold 1,993,571 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of GBX 142 ($1.78), for a total value of £2,830,870.82 ($3,548,791.30). Over the last quarter, insiders have acquired 310 shares of company stock valued at $45,010. Insiders own 32.62% of the company’s stock.

About Oxford Nanopore Technologies

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific.